465 related articles for article (PubMed ID: 17559361)
1. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
2. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
3. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
5. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
6. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice.
Lee K; Yun ST; Kim YG; Yoon Y; Jo EC
Hepatology; 2006 May; 43(5):1063-73. PubMed ID: 16628632
[TBL] [Abstract][Full Text] [Related]
8. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
[TBL] [Abstract][Full Text] [Related]
9. [Transarterial immuno-embolization therapy in patients with hepatocellular carcinoma].
Eguchi H; Takeda T; Sakon M; Umeshita K; Ohzato H; Dono K; Gotoh M; Monden T; Monden M
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1665-7. PubMed ID: 9382502
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma (HCC): current and evolving therapies.
Gish RG; Baron A
IDrugs; 2008 Mar; 11(3):198-203. PubMed ID: 18311657
[TBL] [Abstract][Full Text] [Related]
11. [Hypoxia in hepatocellular carcinoma].
Myung SJ; Yoon JH
Korean J Hepatol; 2007 Mar; 13(1):9-19. PubMed ID: 17380070
[TBL] [Abstract][Full Text] [Related]
12. Transarterial therapies for hepatocellular carcinoma.
Sangro B; D'Avola D; Iñarrairaegui M; Prieto J
Expert Opin Pharmacother; 2011 May; 12(7):1057-73. PubMed ID: 21470073
[TBL] [Abstract][Full Text] [Related]
13. Transarterial embolization with microspheres in the treatment of monofocal HCC.
Nicolini A; Fasani P; Manini MA; Martinetti L; Forzenigo LV; Iavarone M; Crespi S; Rossi G; Biondetti P; Colombo M; Sangiovanni A
Dig Liver Dis; 2009 Feb; 41(2):143-9. PubMed ID: 18436490
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.
Maegdefrau U; Amann T; Winklmeier A; Braig S; Schubert T; Weiss TS; Schardt K; Warnecke C; Hellerbrand C; Bosserhoff AK
J Pathol; 2009 Aug; 218(4):520-9. PubMed ID: 19431154
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy strategies for hepatocellular carcinoma.
Hwang LH
J Biomed Sci; 2006 Jul; 13(4):453-68. PubMed ID: 16633742
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma].
Shimizu J; Kanai T; Monden M; Sakon M; Gotoh M; Umeshita K; Tarui T; Monden T; Mori T; Tomoda K
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1437-40. PubMed ID: 1326909
[TBL] [Abstract][Full Text] [Related]
17. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy.
Bishayee A; Darvesh AS
Curr Cancer Drug Targets; 2012 Nov; 12(9):1095-118. PubMed ID: 22873221
[TBL] [Abstract][Full Text] [Related]
20. Preservation of segment 4 inferior by distal middle hepatic vein reconstruction combined with extended right hepatectomy after portal vein embolization in a patient with a huge initially unresectable HCC.
Nakano H; Kikuchi K; Seta S; Katayama M; Yamamura T; Otsubo T
Hepatogastroenterology; 2007; 54(77):1563-6. PubMed ID: 17708300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
